Literature DB >> 22480597

Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients.

Robert M Post1, Gabriele S Leverich, Lori L Altshuler, Mark A Frye, Trisha Suppes, Susan L McElroy, Paul E Keck, Willem A Nolen, Mike Rowe, Ralph W Kupka, Heinz Grunze, Frederick K Goodwin.   

Abstract

OBJECTIVE: The long-term impact of prior antidepressant exposure on the subsequent course of bipolar illness remains controversial.
METHOD: 139 outpatients (mean age, 42 years) with bipolar I disorder diagnosed by DSM-IV criteria had a detailed retrospective examination of their prior course of illness on the National Institute of Mental Health Life Chart Method. Number of prior antidepressant trials and total duration of antidepressant exposure were assessed. Prospective long-term response (for at least 6 months) to naturalistic treatment in the network from 1996 through 2002 was the primary outcome measure as it related to prior antidepressant exposure (and other illness variables) by logistic regression, with P < .05 used for statistical significance in this post hoc analysis.
RESULTS: Greater number of antidepressant trials, but not duration of antidepressant exposure, was related to prospective nonresponse (P = .0051) whether or not antidepressants were covered by concurrent treatment with a mood stabilizer or atypical antipsychotic. Poor prospective response was also independently related to having had an anxiety disorder and 20 or more prior affective episodes.
CONCLUSIONS: That the number of antidepressant trials, but not duration of antidepressant treatment, was associated with prospective nonresponse suggests that it is the repeated use of antidepressants to treat episodes of depression that is related to poor prospective response to naturalistic treatment. The direction of causality is unclear as to whether more antidepressant trials led to this increased treatment resistance or whether a difficult course of illness with more episodes and anxiety comorbidity engendered more attempts at antidepressant treatment. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480597     DOI: 10.4088/JCP.11m07396

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Illness progression as a function of independent and accumulating poor prognosis factors in outpatients with bipolar disorder in the United States.

Authors:  Robert M Post; Lori L Altshuler; Gabriele S Leverich; Willem A Nolen; Ralph Kupka; Heinz Grunze; Mark A Frye; Trisha Suppes; Susan L McElroy; Paul E Keck; Mike Rowe
Journal:  Prim Care Companion CNS Disord       Date:  2014-12-18

Review 2.  An update on antidepressant use in bipolar depression.

Authors:  Michelle M Sidor; Glenda M MacQueen
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

3.  A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.

Authors:  E Sherwood Brown; John Park; Christine E Marx; Linda S Hynan; Claire Gardner; Domingo Davila; Alyson Nakamura; Prabha Sunderajan; Alexander Lo; Traci Holmes
Journal:  Neuropsychopharmacology       Date:  2014-06-11       Impact factor: 7.853

4.  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Authors:  Isabella Pacchiarotti; David J Bond; Ross J Baldessarini; Willem A Nolen; Heinz Grunze; Rasmus W Licht; Robert M Post; Michael Berk; Guy M Goodwin; Gary S Sachs; Leonardo Tondo; Robert L Findling; Eric A Youngstrom; Mauricio Tohen; Juan Undurraga; Ana González-Pinto; Joseph F Goldberg; Ayşegül Yildiz; Lori L Altshuler; Joseph R Calabrese; Philip B Mitchell; Michael E Thase; Athanasios Koukopoulos; Francesc Colom; Mark A Frye; Gin S Malhi; Konstantinos N Fountoulakis; Gustavo Vázquez; Roy H Perlis; Terence A Ketter; Frederick Cassidy; Hagop Akiskal; Jean-Michel Azorin; Marc Valentí; Diego Hidalgo Mazzei; Beny Lafer; Tadafumi Kato; Lorenzo Mazzarini; Anabel Martínez-Aran; Gordon Parker; Daniel Souery; Ayşegül Ozerdem; Susan L McElroy; Paolo Girardi; Michael Bauer; Lakshmi N Yatham; Carlos A Zarate; Andrew A Nierenberg; Boris Birmaher; Shigenobu Kanba; Rif S El-Mallakh; Alessandro Serretti; Zoltan Rihmer; Allan H Young; Georgios D Kotzalidis; Glenda M MacQueen; Charles L Bowden; S Nassir Ghaemi; Carlos Lopez-Jaramillo; Janusz Rybakowski; Kyooseob Ha; Giulio Perugi; Siegfried Kasper; Jay D Amsterdam; Robert M Hirschfeld; Flávio Kapczinski; Eduard Vieta
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

5.  Eye movement desensitization and reprocessing for posttraumatic stress disorder in bipolar disorder.

Authors:  Daeyoung Oh; Daeho Kim
Journal:  Psychiatry Investig       Date:  2014-07-21       Impact factor: 2.505

6.  Long-term efficacy and safety of lamotrigine for all types of bipolar disorder.

Authors:  Yoshinori Watanabe; Seiji Hongo
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-20       Impact factor: 2.570

Review 7.  25 Years of the International Bipolar Collaborative Network (BCN).

Authors:  Robert M Post; Lori L Altshuler; Ralph Kupka; Susan L McElroy; Mark A Frye; Heinz Grunze; Trisha Suppes; Paul E Keck; Willem A Nolen
Journal:  Int J Bipolar Disord       Date:  2021-04-02

Review 8.  Antidepressant chronotherapeutics for bipolar depression.

Authors:  Francesco Benedetti
Journal:  Dialogues Clin Neurosci       Date:  2012-12       Impact factor: 5.986

9.  Risk factors of cycle acceleration in acutely admitted patients with bipolar disorder.

Authors:  P I Finseth; G Morken; U F Malt; O A Andreassen; A E Vaaler
Journal:  Acta Psychiatr Scand       Date:  2014-06-24       Impact factor: 6.392

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.